Analyst Mohit Bansal of Wells Fargo maintained a Hold rating on Pfizer, retaining the price target of $28.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Mohit Bansal has given his Hold rating due to a combination of factors surrounding Pfizer’s current financial and strategic positioning. The company has shown positive signs with its cost-saving initiatives, which have allowed for an upward revision in its earnings per share guidance for 2025. Despite these improvements, Pfizer has maintained a conservative revenue outlook, particularly concerning potential fluctuations in COVID-related revenues for the second half of the year.
Furthermore, Pfizer is actively engaging in policy discussions with the administration regarding tariffs and other regulatory matters, which could impact its future financial performance. While the company is optimistic about its earnings growth, driven by operational efficiency and R&D productivity, the ongoing investments in its pipeline and the cautious stance on COVID revenue guidance suggest a balanced risk-reward scenario. Consequently, Bansal’s Hold rating reflects a cautious optimism, acknowledging both the potential for growth and the uncertainties that lie ahead.
In another report released today, Bank of America Securities also reiterated a Hold rating on the stock with a $28.00 price target.
PFE’s price has also changed slightly for the past six months – from $26.440 to $24.750, which is a -6.39% drop .